These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7971251)

  • 1. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
    Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
    Delannoy A; Ferrant A; Martiat P; Bosly A; Zenebergh A; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):317-20. PubMed ID: 7971252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
    O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
    N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Chlorodeoxyadenosine treatment of patients with chronic lymphocytic leukaemia associated with autoimmune haemolysis.
    Zaucha JM; Hałaburda K; Ciepłuch H; Hellmann A
    Acta Haematol Pol; 1994; 25(2):119-27. PubMed ID: 7915075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
    Herrero M; Cabrera JR; Briz M; Forés R; Díez JL; Regidor C; Sanjuán I; Fernández MN
    Sangre (Barc); 1995 Apr; 40(2):115-9. PubMed ID: 7784940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
    Robak T
    Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
    Montillo M; Tedeschi A; O'Brien S; Di Raimondo F; Lerner S; Ferrajoli A; Morra E; Keating MJ
    Cancer; 2003 Jan; 97(1):114-20. PubMed ID: 12491512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
    Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T; Blonski JZ; Wawrzyniak E; Gora-Tybor J; Palacz A; Dmoszynska A; Konopka L; Warzocha K; Jamroziak K
    Cancer; 2009 Jan; 115(1):94-100. PubMed ID: 19025975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).
    Delannoy A; Martiat P; Gala JL; Deneys V; Ferrant A; Bosly A; Schieff JM; Michaux JL
    Leukemia; 1995 Jul; 9(7):1130-5. PubMed ID: 7630184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
    Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
    Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.